{
    "clinical_study": {
        "@rank": "90649", 
        "arm_group": [
            {
                "arm_group_label": "Chemoradiotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Pre-operative chemoradiotherapy arm:\nRadiotherapy (45Grey/25F) + chemotherapy:(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles) then receive Surgical resection after surgery get post-operative chemotherapy with the same dose as pre-operative"
            }, 
            {
                "arm_group_label": "Chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Pre-operative chemotherapy arm:\nChemotherapy:(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles) then receive Surgical resection after surgery get post-operative chemotherapy with the same dose as pre-operative"
            }
        ], 
        "brief_summary": {
            "textblock": "Background: It has been shown that the patitents with gastric cancer could benefits from\n      peri-operative chemoradiotherapy, but whether the pre-operative chemoradiotherapy can\n      improve patitents' outcome is still unclear.\n\n      Patients and methods: In this study , patients with histologically confirmed gastric cancer\n      whose pre-operative staging are cT4 any N,MO, aged from 18 to 70 years and with Eastern\n      Cooperative Oncology Group performance status \u22642 and adequate organ function, are randomized\n      1:1 to receive pre-operative chemoradiotherapy with DT45Gy/25f plus two cycles of\n      XELOX(Xeloda 1000mg/m2, BID, DI-D14; Oxaliplatin 130mg/m2 on day 1;,21-days per cycle) or\n      chemotherapy alone then following by surgical resection and adjuvant chemotherapy with XELOX\n      at the same dose up to 4 cycles. The primary end point is overall survival (OS), and\n      secondary end point is disease free survival(DFS) and safety. Final study analysis will be\n      conducted in the end of the 5th year after the last patient's enrollment."
        }, 
        "brief_title": "Pre-operative Chemoradiotherapy or Chemotherapy Following Surgery and Adjuvent Chemotherapy in Patients With Gastric Cancer", 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  informed consensus of patients\n\n          -  be able to receive oral administration\n\n          -  from 18 to 70 years old\n\n          -  be proven to be primary adenocarcinoma of gastric cancer and pre-operative staging\n             cT4, any N,MO,\n\n          -  without other chemotherapy and/or radiation against to the disease\n\n          -  normal function of other organs including heart,liver ,kidney and so on\n\n          -  Eastern Cooperative Oncology Group performance status:0~2\n\n        Exclusion Criteria:\n\n          -  history of other malignancy\n\n          -  allergic reaction to xeloda or oxaliplatin\n\n          -  be enrolling in other clinical trials\n\n          -  abnormal GI tract function\n\n          -  dysfunction of other organs\n\n          -  female in pregnancy or lactation,or refuse to receive Contraception measures during\n             chemotherapy\n\n          -  other situation to be judged not adaptive to the study by investigators"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "620", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815853", 
            "org_study_id": "SYSUCCGPS2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chemoradiotherapy", 
                "description": "Pre-operative chemoradiotherapy arm:\nRadiotherapy (45Grey/25F) + chemotherapy(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles)", 
                "intervention_name": "Pre-operative chemoradiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "Chemoradiotherapy", 
                    "Chemotherapy"
                ], 
                "description": "chemotherapy:(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles)", 
                "intervention_name": "Capecitabine,Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Capecitabine: Xeloda", 
                    "Oxaliplatin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pre-operative,", 
            "chemoradiotherapy,", 
            "chemotherapy,", 
            "treatment", 
            "outcome"
        ], 
        "lastchanged_date": "March 21, 2013", 
        "location": {
            "contact": {
                "email": "sunxw@sysucc.org.cn", 
                "last_name": "Xiao-wei Sun, MD", 
                "phone": "86-20-87343123"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }, 
            "investigator": {
                "last_name": "Zhi-wei Zhou, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "measure": "radical resection rate", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "overall_contact": {
            "email": "zhouzhw@sysucc.org.cn", 
            "last_name": "Zhi-wei Zhou, M.D,Ph.D", 
            "phone": "86-20-87343626"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China:Clinical Trial Center", 
                "China: Sun Yat-sen University Cancer Center"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Total Survival", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815853"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Zhou Zhiwei", 
            "investigator_title": "Director of Gastric and Pancreatic Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Disease Free Survival", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}